Mr. Miguel Martin reports

AURORA CANNABIS FURTHERS GLOBAL MEDICAL CANNABIS GROWTH WITH ACCRETIVE ACQUISITION OF INTERNODE PHARMA LIMITED AND HAP PHARMA LIMITED, EXPANDING DISTRIBUTION ACCESS TO THE UK MEDICAL CANNABIS MARKET

Aurora Cannabis Inc. has acquired Internode Pharma Ltd., a licensed importer and wholesaler, and HAP Pharma Ltd., a licensed pharmacy.

"The acquisition of Internode Pharma Ltd. and HAP Pharma Ltd. mark a further strategic milestone for Aurora as we continue to purposefully invest in expanding our leadership in the rapidly growing international medical cannabis market. We believe that this transaction will allow us to fully leverage our operational, commercial and regulatory expertise to expand our market share, while also supporting a consistent and reliable supply of high-quality medical cannabis products to U.K. patients," said Miguel Martin, executive chairman and chief executive officer of Aurora.

"Given the growing patient demand, strong acceptance of our products and increasingly prescriptive regulatory standards, the U.K. represents an exciting opportunity for us, and acquiring these companies provides Aurora with greater agility to more reliably serve U.K. patients," added Mr. Martin.

Strategic rationale

• The United Kingdom is one of the largest European medical cannabis markets, representing a population of approximately 70 million people.
• The companies operate a licensed import and distribution facility and a virtual pharmacy in Birmingham, U.K., providing Aurora with direct ownership and control of the supply chain from cultivation through to delivery to patients.
• Aurora intends to leverage its commercial, regulatory and operational expertise to streamline distribution and drive market share gains in the rapidly growing UK medical cannabis market.
• This transaction is expected to be accretive to adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) contributions in future quarters due to operational efficiencies and reduced reliance on third parties to distribute Aurora's products to patients.
• Aurora intends to evaluate further investment opportunities to expand distribution capacity in the U.K. to support increasing patient demand.

Transaction details

Aurora, through a wholly owned subsidiary, indirectly purchased 100 per cent of the shares of Internode Pharma and HAP Pharma. As consideration on closing, Aurora paid the selling shareholders 2.1 million pounds sterling in cash, contingent on the satisfaction of certain conditions post-closing.

About Aurora Cannabis Inc.

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler Medical Marijuana Co. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of opening the world to cannabis.

We seek Safe Harbor.